| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2005-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e3a9910edb97b2c47a3310e4e3bfeec |
| publicationDate |
2013-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2583685-A1 |
| titleOfInvention |
Method of administering and using VEGF inhibitors for the treatment of human cancer |
| abstract |
A vascular endothelial growth factor (VEGF) antagonist for use in a method of treating a human patient suffering from cancer, where the antagonist comprises a dimer of two fusion polypeptides, each fusion polypeptide comprising (a) an immunoglobulin (Ig)-like domain 2 of a FIt-1 and Ig domain 3 of an Flk-1 or Flt-4, and (b) a multimerizing component, where the method comprises: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist that are approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019083172-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106049-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020106050-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017195874-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020159171-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020159203-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190045827-A |
| priorityDate |
2004-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |